Global Melanoma Therapeutics Market Analysis and Forecast 2015-2019

Global Melanoma Therapeutics Market 2015-2019 is a new market research publication announced by Reportstack. According to Melanoma Research Foundation, melanoma is usually, but not always, a cancer of the skin. Melanoma is defined as a cancer that occurs in melanocytes (cells that make the pigment melanin). Chest and back in men and legs in women are the most likely parts to be affected with melanoma. CM, MM, and OM are the three major categories of melanoma. The exact etiology of melanoma is unknown. According to the American Skin Association, the incidence of melanoma is increasing worldwide. The median age of diagnosis is 59 years and the median age of death due to melanoma is 67 years.

The analysts forecast that the Global Melanoma Therapeutics market to grow at a CAGR of 15.40 percent over the period 2014-2019.

To access full report with TOC, please visit Global Melanoma Therapeutics Market 2015-2019.

Covered in this Report
This report covers the present scenario and the growth prospects of the Global Melanoma Therapeutics market for the period 2015-2019. To calculate the market size, the report considers the revenue generated from the sales of various drugs used in the treatment of melanoma that are available in the market. The market is divided into four segments: CM, OM, MM, and Others.

The report, Global Melanoma Therapeutics Market 2015-2019, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the Americas, and the EMEA and APAC regions; it also covers the market landscape and its growth prospects in the coming years. The report also includes a discussion of the key vendors operating in this market.

Key Regions
• Americas 

Key Vendors
• Merck
• Roche

Other Prominent Vendors
• AB Science
• Amgen
• Bayer
• Celgene
• Daiichi Sankyo
• Eisai
• Galectin Therapeutics
• Novartis
• Pfizer
• Vical


Debora White
Manager - Marketing
Ph: +1-888-789-6604
Reportstack Market Research